Age (years)
|
55.1 (10.99)
|
52.2 (12.84)
|
Female, n (%)
|
149 (85.1)
|
131 (78.9)
|
Race,a n (%)
|
Caucasian
|
169 (96.6)
|
164 (98.8)
|
Functional RA status, n (%)
|
Class I
|
20 (11.4)
|
25 (15.1)
|
Class II
|
122 (69.7)
|
121 (72.9)
|
Class III
|
33 (18.9)
|
20 (12.0)
|
DAS28-CRP
|
5.42 (0.92)
|
5.54 (0.78)
|
DAS28-ESR
|
6.34 (0.88)
|
6.42 (0.76)
|
Tender 28 joint count
|
14.1 (6.21)
|
14.5 (5.57)
|
Swollen 28 joint count
|
10.6 (5.22)
|
11.0 (5.39)
|
C-reactive protein (mg/L)
|
12.0 (21.63)
|
11.3 (16.34)
|
HAQ-DI score
|
1.45 (0.55)
|
1.47 (0.56)
|
FACIT-fatigue score
|
26.82 (9.55)
|
25.32 (10.14)
|
Duration of rheumatoid arthritis (years)
|
8.75 (8.22)
|
8.11 (6.93)
|
Rheumatoid factor, positive,b n (%)
|
130 (74.30)
|
118 (71.10)
|
Anti-CCP, positive, b n (%)
|
138 (78.90)
|
119 (71.70)
|
Prior therapy,c n (%)
|
MTX only
|
53 (30.3)
|
46 (27.7)
|
MTX + any DMARDs
|
68 (38.9)
|
69 (41.6)
|
MTX + any anti-TNF
|
30 (17.1)
|
28 (16.9)
|
MTX + any other biologic
|
24 (13.7)
|
23 (13.9)
|
Previous DMARDs used, n (%)
|
1
|
53 (30.3)
|
46 (27.7)
|
2
|
69 (39.4)
|
62 (37.3)
|
3
|
34 (19.4)
|
39 (23.5)
|
4 or more
|
19 (10.9)
|
19 (11.4)
|
MTX dose (mg/week)
|
16.0 (4.9)
|
17.0 (4.7)
|
Duration of MTX (months)
|
56.3 (49.9)
|
59.3 (52.4)
|